Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-08-07 , DOI: 10.1016/s1470-2045(24)00318-8
Jean-Yves Blay ₁ , Quentin Devin ₁ , Florence Duffaud ₂ , Maud Toulmonde ₃ , Nelly Firmin ₄ , Olivier Collard ₅ , Emmanuelle Bompas ₆ , Benjamin Verret ₇ , Isabelle Ray-Coquard ₁ , Sebastien Salas ₂ , Clemence Henon ₇ , Charles Honoré ₈ , Mehdi Brahmi ₁ , Armelle Dufresne ₁ , Marc Pracht ₉ , Alice Hervieu ₁₀ , Nicolas Penel ₁₁ , Francois Bertucci ₁₂ , Maria Rios ₁₃ , Esma Saada-Bouzid ₁₄ , Pauline Soibinet ₁₅ , David Perol ₁₆ , Sylvie Chabaud ₁₆ , Antoine Italiano ₃ , Axel Le Cesne ₁₇

Affiliation

Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Hopital La Timone, Marseille, France.
Institut Bergonié, Bordeaux, France.
Institut de Cancérologi Val d'Aurelle, Montpellier, France.
Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Hopitaux Privés de la Loire, St Etienne, France.
Institut de Cancérologie de l'Ouest, Nantes, France.
Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.
Hopitaux Privés de la Loire, St Etienne, France.
Centre Eugene Marquis, Rennes, France.
Centre George-François Leclerc, Dijon, France.
Centre Oscar Lambret, Lille, France.
Institut Paoli-Calmettes, Marseille, France.
Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.
Centre Antoine Lacassagne, Nice, France.
Institut Jean Godinot, Reims, France.
Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.
Institut Gustave Roussy, Villejuif, France.

The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial.

中文翻译：

晚期胃肠道间质瘤（BFR14）患者停用伊马替尼与继续使用伊马替尼：一项开放标签、多中心、随机、3 期试验的探索性长期随访

停用酪氨酸激酶抑制剂（TKI）对晚期胃肠道间质瘤（GIST）患者耐药和生存的长期影响尚不清楚。我们在 BFR14 试验中报告了晚期 GIST 患者停用伊马替尼的探索性长期结局。

更新日期：2024-08-07

点击分享查看原文

点击收藏

阅读更多本刊新发论文